Valuation
- Market cap
- 112,495,000
- Revenue TTM
- $33,030,000
- Net income TTM
- $-44,630,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- -135.12%
- Debt to equity
- 0.00
Trading
- Volume
- 228,100
- Avg volume
- 613,514
- Day's range
- $1.07 – $1.11
- Shares out
- 103,206,000
- Stochastic %K
- 0%
- Beta
- 1.49
- Analysts
- Strong Sell
- Price target
- $4.67
Company profile
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GT...
Show more
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. The company has strategic partnership with VectorBuilder focused on co-developing a new gene delivery solution. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
- Industry
- Medical Devices
- Sector
- Healthcare
- Phone
- 301 944 1700
- Website
- https://www.maxcyte.com
- Address
- 9713 Key West Avenue, Suite 400, Rockville, United States
Latest news
No headlines yet.
Stocktwits
burbs88
Aug 13, 1:44 PM
$MXCT What a beautiful bear trap that was.
0 replies
EarningsInsider
Aug 12, 9:32 PM
https://www.marketbeat.com/earnings/reports/2026-8-12-maxcyte-inc-stock/
$MXCT MaxCyte Earnings Transcript
0 replies
StocktwitsEarnings
Aug 12, 8:21 PM
$MXCT Q2 '26 Earnings Results & Recap
• Reported GAAP EPS of -
$0.08 up 33.33% YoY
• Reported revenue of
$7.27M down -14.53% YoY
• MaxCyte expects full year 2026 revenue of
$30 million to
$32 million, consisting of
$25 million to
$27 million in core revenue and approximately
$5 million in SPL Program-related revenue.
0 replies
Hertha
Aug 12, 10:45 AM
$MXCT
You can extrapolate from VRTX and CRSP: they mentioned good numbers and MXCT is their tollbooth.
All this doesn’t take away from the fact: we need to wait until 2028 or later until we know if this is a good investment.
1 replies
HypnoTrader
Aug 12, 2:17 AM
$MXCT up 14% overnight. Earnings are not untill tomorrow afternoon....
1 replies